Enliven Therapeutics (ELVN) Deferred Taxes (2019 - 2020)
Enliven Therapeutics (ELVN) reported Deferred Taxes of -$7000.0 for Q4 2020, down 200.0% on a YoY basis from $7000.0 in Q1 2020, and down 16.67% sequentially from -$6000.0 in Q3 2020.
Enliven Therapeutics (ELVN) Deferred Taxes (2019 - 2020) Analysis & Trends
Enliven Therapeutics (ELVN) has 2 years of Deferred Taxes data on file, last reported at -$7000.0 in Q4 2020.
- For the quarter ending Q4 2020, Deferred Taxes fell 200.0% year-over-year to -$7000.0; the trailing twelve-month figure through Dec 2020 stood at -$24000.0 (changed N/A YoY), and the FY2020 full-year result was -$24000.0, down 124.0% from the prior year.
- Deferred Taxes eased to -$7000.0 in Q4 2020, from -$6000.0 in the prior quarter.
- In the past five years, Deferred Taxes ranged from a high of $61000.0 in Q3 2019 to a low of -$7000.0 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -188,883.60 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -65.30 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 96.00 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Enliven Therapeutics | 3.22 Bn | 3.22 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | -7,000.00 |
| Sep 30, 2020 | -6,000.00 |
| Jun 30, 2020 | -6,000.00 |
| Mar 31, 2020 | -5,000.00 |
| Dec 31, 2019 | 7,000.00 |
| Sep 30, 2019 | 61,000.00 |